IP Library Granted Patent US 9,670,520
Granted Patent B2
US 9,670,520 · App. 15/144,223 · Granted Jun 6, 2017

Process for the culturing of cells

Inventors: Gerben Meile Zijlstra (Groningen, NL); Robert Patrick Hof (Groningen, NL); Jacob Schilder (Kropswolde, NL)
Assignee: Patheon Holdings | B.V.
C12P21/00B01D15/26B01D69/08C07K1/18C07K1/22C07K1/34C07K16/00C12N5/0603C12N5/0621C12P21/005C12N2500/32C12N2500/90C12N2500/92C12N2500/99C12N2510/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,670,520
App. No.
15/144,223
Granted
Jun 6, 2017
Kind
B2
Abstract

The invention relates to a process for the culturing of cells, preferably E1-immortalized HER cells, more preferably PER.C6 cells in a reactor in suspension in a cell culture medium, wherein the cells produce a biological substance, preferably an antibody, wherein at least one cell culture medium component is fed to the cell culture and wherein the cell culture comprising the cells, the biological substance and cell culture medium is circulated over a separation system and wherein the separation system separates the biological substance from substances having a lower molecular weight than the biological substance and wherein the biological substance is retained in or fed back into the reactor. Preferably part of the substances of lower molecular weight is continuously removed from the cell culture.

Claims (24)

1. Process for the culturing of cells in a reactor in suspension in a cell culture medium, comprising:

circulating a cell culture through a separation system,

wherein the cell culture comprises eukaryotic cells, a biological substance produced by the cells, and a cell culture medium;

wherein the biological substance is an IgG;

wherein at least one cell culture medium component is fed to the cell culture;

wherein the cell culture is circulated through the separation system in a flow substantially parallel to a surface of said separation system resulting in a liquid outflow and a flow wherein cell culture contents are retained or fed back into the reactor;

wherein the separation system comprises a filter having a pore size characterized by a molecular weight cut-off smaller than the molecular weight of the biological substance to separate the biological substance from substances having a lower molecular weight than the biological substance;

wherein the liquid outflow consists essentially of components having molecular weight lower than that of the biological substance and the flow wherein cell culture contents are retained or fed back into the reactor consists essentially of components having molecular weight equal to or higher than that of the biological substance;

wherein the cell culture is removed at least once from the reactor, and

wherein the biological substance is harvested from the cells and/or from the cell culture.

2. Process according to claim 1 , wherein the filter comprises a membrane filter.

3. Process according to 2 , wherein the membrane filter comprises a hollow fiber filter.

4. Process according to claim 2 or 3 wherein the filter has a pore size with a molecular weight cut-off of at most 100 kDa.

5. Process according to claim 4 , wherein the filter has a pore size with a molecular weight cut-off of at most 50 kDa.

6. Process according to claim 5 , wherein the filter has a pore size with a molecular weight cut-off of at most 30 kDa.

7. Process according to claim 1 , wherein the molecular weight cut-off is smaller by at least a factor of 2 than the molecular weight of the IgG.

8. Process according to claim 1 , wherein the molecular weight cut-off is smaller by at least a factor of 3 than the molecular weight of the IgG.

9. Process according to claim 1 wherein the cell culture is circulated through the filter in an alternating tangential flow.

10. Process according to claim 1 wherein the cell culture is circulated through the filter in a unidirectional tangential flow.

11. Process according to claim 1 , wherein part of the substances of lower molecular weight is continuously removed from the cell culture.

12. Process according to claim 1 , wherein the cells are mammalian cells.

13. Process according to claim 12 , wherein the mammalian cells are selected from the group consisting of Chinese hamster ovary (CHO) cells, hybridomas, baby hamster kidney (BHK) cells, myeloma cells, human cells, or mouse cells.

14. Process according to claim 13 , wherein the mammalian cells are Chinese hamster ovary (CHO) cells.

15. Process according to claim 1 , wherein the harvesting comprises subjecting the cell culture to affinity chromatography and/or ion exchange chromatography.

Assignments (2)
CHANGE OF NAME Recorded Feb 9, 2017
From: DPX HOLDINGS B.V.
To: PATHEON HOLDINGS I B.V.
Reel/Frame 041670/0961 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2016
From: ZIJLSTRA, G. M.; HOF, R. P.; SCHILDER, J.
To: DPX HOLDINGS B.V.
Reel/Frame 038477/0259 →
Priority Claims (2)
GB 06014671.9 · Jul 14, 2006 · national
GB 07002571.3 · Feb 6, 2007 · national
Continuity (5)
Continuation 14175172 · Feb 7, 2014
Continuation 13707115 · Dec 6, 2012
Continuation 13372069 · Feb 13, 2012
Continuation 12307995
Related Publication 20160265017A1 · Sep 15, 2016